Oral Semaglutide Pharmacokinetics in Healthy Chinese Adults: A Phase 1 Trial
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
Semaglutide and Kidney Health
In the FLOW trial, once-weekly semaglutide lowered major kidney disease events by 24% in type 2 diabetes with chronic kidney disease. PICO summary and expert commentary.
SURPASS-2 Post Hoc: Tirzepatide vs Semaglutide on Beta-Cell Function and Insulin Sensitivity
A post hoc analysis of the SURPASS-2 phase 3 trial comparing tirzepatide and semaglutide on HOMA2 markers of beta-cell function and insulin sensitivity in type 2 diabetes. PICO summary and expert commentary.
Tirzepatide in Early-Onset Type 2 Diabetes: SURPASS Post Hoc Analysis
A post hoc analysis of the SURPASS program found tirzepatide produced similar HbA1c, weight, and cardiometabolic improvements whether type 2 diabetes was diagnosed before or after age 40. PICO summary and expert commentary.
Semaglutide and Heart Failure in Diabetes
STEP-HFpEF DM: once-weekly semaglutide 2.4 mg improved symptoms, weight, and exercise capacity versus placebo in obese, diabetic patients with HFpEF. PICO summary and expert commentary.
Cotadutide in Diabetic Kidney Disease (Phase 2b)
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.
Integrated Digital Data Platform Plus Dietary Management in Type 2 Diabetes: A 12-Week RCT
A single-center randomized controlled trial testing a cloud-hospital data platform plus dietary management against standard care in 180 adults with type 2 diabetes, reporting a modest 12-week HbA1c advantage. PICO summary and expert commentary.
Semaglutide and Primary Prevention of Diabetic Kidney Disease (SUSTAIN 6 Post Hoc)
A post hoc analysis of SUSTAIN 6 suggesting once-weekly semaglutide lowered new-onset diabetic kidney disease in type 2 diabetes. PICO summary and expert commentary.
Semaglutide Efficacy Across Baseline Subgroups: A Post Hoc Analysis of SUSTAIN China
A post hoc analysis of the SUSTAIN China trial found that the glycaemic efficacy of once-weekly semaglutide versus sitagliptin was consistent across most baseline subgroups. PICO summary and expert commentary.
IcoSema Pharmacokinetics: Insulin Icodec and Semaglutide Fixed-Ratio Combination Versus Separate Administration
A phase 1 crossover study of the IcoSema fixed-ratio combination of insulin icodec and semaglutide reports unchanged icodec exposure but a higher, earlier semaglutide peak versus separate injections. PICO summary and expert commentary.